The most recent short interest data was recently released by the NASDAQ for the 08/29/2014 settlement date, and Halozyme Therapeutics Inc (HALO) is one of the most shorted stocks of the Russell 3000, based on 22.51 "days to cover" versus the median component at 7.91. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.In the case of Halozyme Therapeutics Inc ( HALO), the total short interest at the 08/29/2014 settlement date was 17,898,113 shares, which compares to the average daily trading volume of just 795,252 shares, for a "days to cover" ratio of 22.51. When short sellers eventually cover their positions, by definition there must be buying activity because a share that is currently sold short must be purchased to be covered. At the present levels of short interest, if from this point forward every single HALO share traded represented a short position being closed, then at the average daily volume of 795,252 shares it would only be during the 23rd trading day that every short position would be closed.
So it would stand to reason that should some unexpectedly good news come out, and short sellers did not have 23 days of patience but instead wanted to cover their short positions very suddenly, that situation could result in sending the stock higher until the higher price produces enough sellers to generate the necessary volume to close out those positions quickly.Halozyme Therapeutics Inc ( HALO) has something relatively rare for a stock with this much short interest, that being insiders taking the other side of the trade. Looking back over the trailing six month period, HALO has seen 2 different instances of insider buying, as summarized by the table below:
|09/16/2014||David A. Ramsay||VP and Chief Financial Officer||25,000||$8.90||$222,500.00|
|09/16/2014||Helen Torley||President and CEO||50,000||$8.92||$446,000.00|
In recent trading, shares of Halozyme Therapeutics Inc ( HALO) were changing hands at $9.72/share.